Development and Validation of a New Stability-indicating RP-HPLC Method for the Quantification of Etoricoxib in Tablets
Main Article Content
Abstract
Introduction: Etoricoxib is also a bipyridine derivative used as a non-steroidal anti-inflammatory drug. A new
stability-indicating reverse phase high-performance liquid chromatographic (HPLC) method has been developed
for the quantification of Etoricoxib in tablet dosage forms. Materials and Methods: A Shimadzu HPLC system
equipped Agilent C18 column was chosen for the chromatographic study with mobile phase formic acid:acetonitrile
(52:48) and a flow rate of 0.8 mL/min (UV detection at 247 nm). Results and Discussion: Linearity was obeyed
over the concentration range of 0.5–100 μg/mL with a linear regression equation y = 95013× – 11970 and a
correlation coefficient of 0.9998. The limit of detection and limit of quantification were found to be 0.1557 and
0.4791 μg/mL, respectively. Stress degradation studies were performed, and the method was validated as per the
International Council for Harmonisation guidelines. Conclusion: The RP-HPLC method so developed was found
to be selective, specific, precise, accurate, robust, and useful for the estimation of Etoricoxib tablets.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.